Published in Int J Cancer on July 03, 1997
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res (2000) 3.41
Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol (1999) 2.93
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev (2010) 2.57
Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal (2010) 2.56
Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol (1999) 2.35
Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol (1998) 2.22
uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol (2007) 2.11
Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol Biol Cell (2001) 2.09
Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci U S A (1999) 2.01
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol (2001) 1.94
Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol (2001) 1.68
Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol (2001) 1.57
Mathematical modeling of tumor-induced angiogenesis. J Math Biol (2004) 1.51
Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut (1998) 1.50
Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells. Cancer Biol Ther (2005) 1.49
Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding. J Cell Biol (2005) 1.44
Protein-binding RNA aptamers affect molecular interactions distantly from their binding sites. PLoS One (2015) 1.42
Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus. J Virol (2002) 1.41
Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc Natl Acad Sci U S A (2003) 1.38
RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther (2008) 1.38
PAI-1: An Integrator of Cell Signaling and Migration. Int J Cell Biol (2011) 1.37
Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biol (2004) 1.35
Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol (2005) 1.35
Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther (2005) 1.33
Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res (2008) 1.26
Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol (2002) 1.24
RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer (2007) 1.23
Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness. Mol Biol Cell (2004) 1.22
The molecular and cellular origins of Hodgkin's disease. J Exp Med (2000) 1.21
Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res (2007) 1.21
Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia (2008) 1.20
Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol (2005) 1.20
Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol (2011) 1.18
Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem Biol (2012) 1.17
Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer (2000) 1.15
Moderate folate depletion modulates the expression of selected genes involved in cell cycle, intracellular signaling and folate uptake in human colonic epithelial cell lines. J Nutr Biochem (2007) 1.14
Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. Proc Natl Acad Sci U S A (2008) 1.14
Pocket protein-independent repression of urokinase-type plasminogen activator and plasminogen activator inhibitor 1 gene expression by E2F1. Mol Cell Biol (2000) 1.14
PAI-1 mediates the TGF-beta1+EGF-induced "scatter" response in transformed human keratinocytes. J Invest Dermatol (2010) 1.13
The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am J Pathol (2005) 1.13
Hypoxic tumor microenvironments reduce collagen I fiber density. Neoplasia (2010) 1.12
Sphingosine-1-phosphate regulates glioblastoma cell invasiveness through the urokinase plasminogen activator system and CCN1/Cyr61. Mol Cancer Res (2009) 1.12
Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. Am J Pathol (2001) 1.12
Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Res (2009) 1.09
Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J Cell Biol (1998) 1.09
Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells. Proc Natl Acad Sci U S A (1999) 1.08
Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am J Pathol (2001) 1.08
Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer (2006) 1.07
Death receptors as targets for anti-cancer therapy. J Cell Mol Med (2008) 1.07
A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival. PLoS One (2006) 1.07
The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol (2003) 1.05
Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer (2009) 1.05
Blood peptidome-degradome profile of breast cancer. PLoS One (2010) 1.04
Extracellular proteases as targets for drug development. Curr Protein Pept Sci (2009) 1.02
ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin Exp Metastasis (1999) 1.01
Functional convergence of signalling by GPI-anchored and anchorless forms of a salamander protein implicated in limb regeneration. J Cell Sci (2010) 1.01
PAI-1 Regulates the Invasive Phenotype in Human Cutaneous Squamous Cell Carcinoma. J Oncol (2010) 1.01
Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor. Bioorg Med Chem (2012) 1.01
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer (1998) 1.01
Invasiveness of hepatocellular carcinoma cell lines: contribution of membrane-type 1 matrix metalloproteinase. Neoplasia (1999) 1.00
Mathematical modeling of cancer cell invasion of tissue: biological insight from mathematical analysis and computational simulation. J Math Biol (2010) 1.00
Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. Bioorg Med Chem (2013) 1.00
Bacterial plasminogen receptors: mediators of a multifaceted relationship. J Biomed Biotechnol (2012) 0.99
Soluble N-cadherin fragment promotes angiogenesis. Clin Exp Metastasis (2006) 0.99
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br J Cancer (2001) 0.99
Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem J (2001) 0.99
Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer. BMC Cancer (2014) 0.98
Schwann Cell Migration Induced by Earthworm Extract via Activation of PAs and MMP2/9 Mediated through ERK1/2 and p38. Evid Based Complement Alternat Med (2011) 0.98
Family history of cancer and risk of colorectal cancer in Italy. Br J Cancer (1998) 0.98
Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover. Neoplasia (2008) 0.97
Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast Cancer Res (2007) 0.96
Fingolimod for the treatment of neurological diseases-state of play and future perspectives. Front Cell Neurosci (2014) 0.96
Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1. J Biol Chem (2011) 0.96
Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS One (2013) 0.96
Complex Regulation of the Pericellular Proteolytic Microenvironment during Tumor Progression and Wound Repair: Functional Interactions between the Serine Protease and Matrix Metalloproteinase Cascades. Biochem Res Int (2012) 0.96
A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis. J Biol Chem (2005) 0.94
NAHA, a novel hydroxamic acid-derivative, inhibits growth and angiogenesis of breast cancer in vitro and in vivo. PLoS One (2012) 0.94
Gene expression profile and genomic alterations in colonic tumours induced by 1,2-dimethylhydrazine (DMH) in rats. BMC Cancer (2010) 0.94
Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion. ACS Chem Biol (2011) 0.94
Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines. Br J Cancer (2003) 0.93
Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients. Oncol Lett (2011) 0.92
PAI-1 is a Critical Upstream Regulator of the TGF-beta1/EGF-Induced Invasive Phenotype in Mutant p53 Human Cutaneous Squamous Cell Carcinoma. J Biomed Biotechnol (2007) 0.92
Cooperation between monocytes and breast cancer cells promotes factors involved in cancer aggressiveness. Br J Cancer (2003) 0.91
Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1. Biochem J (2003) 0.91
Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein. Biochem J (2001) 0.90
Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis. Mediators Inflamm (2015) 0.90
The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS (2008) 0.90
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax (1999) 0.90
Cross-talk of anosmin-1, the protein implicated in X-linked Kallmann's syndrome, with heparan sulphate and urokinase-type plasminogen activator. Biochem J (2004) 0.90
Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol (2008) 0.89
Vitamin D3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture. Virchows Arch (2003) 0.89
Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. Br J Cancer (1999) 0.89
Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2. Br J Cancer (2003) 0.89
3-Bromophenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate inhibits cancer cell invasion in vitro and tumour growth in vivo. Br J Cancer (2003) 0.89
Humoral innate immune response and disease. Clin Immunol (2012) 0.89
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Br J Cancer (1999) 0.89
Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease. Br J Cancer (2003) 0.89
PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature (1993) 8.83
A natural language parsing system for encoding admitting diagnoses. Proc AMIA Annu Fall Symp (1997) 2.34
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Efficient pH-independent sequence-specific DNA binding by pseudoisocytosine-containing bis-PNA. Nucleic Acids Res (1995) 2.07
Defining incident vertebral deformity: a prospective comparison of several approaches. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res (1999) 1.55
The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene (2007) 1.53
The overnight dexamethasone test is a worthwhile screening procedure. Clin Endocrinol (Oxf) (1990) 1.52
Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol (2008) 1.51
Effect of different stocking densities during transport on welfare and meat quality in Danish slaughter pigs. Meat Sci (1998) 1.48
Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. J Natl Cancer Inst (1997) 1.47
Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest (1995) 1.44
Anticonvulsant activities of some arylsemicarbazones displaying potent oral activity in the maximal electroshock screen in rats accompanied by high protection indices. J Med Chem (1993) 1.42
Comparative genomic hybridization reveals a recurrent pattern of chromosomal aberrations in severe dysplasia/carcinoma in situ of the cervix and in advanced-stage cervical carcinoma. Genes Chromosomes Cancer (1999) 1.40
High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer (1999) 1.40
Re: urokinase and urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines. J Natl Cancer Inst (1997) 1.39
Serum tumour markers: how to order and interpret them. BMJ (2009) 1.37
Medication management. Hosp Community Psychiatry (1990) 1.37
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol (2006) 1.37
Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer (1995) 1.35
Activin is an essential early mesenchymal signal in tooth development that is required for patterning of the murine dentition. Genes Dev (1998) 1.30
Identification of a highly mobilizable subset of human neutrophil intracellular vesicles that contains tetranectin and latent alkaline phosphatase. J Clin Invest (1990) 1.28
Objective measurement of breast cancer oestrogen receptor status through digital image analysis. Eur J Surg Oncol (2003) 1.26
Increased DNA binding and sequence discrimination of PNA oligomers containing 2,6-diaminopurine. Nucleic Acids Res (1997) 1.25
HER-2 signaling and inhibition in breast cancer. Curr Cancer Drug Targets (2009) 1.25
Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol (2011) 1.23
Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides. Eur J Biochem (1998) 1.20
Overexpression of the Ets-1 transcription factor in human breast cancer. Br J Cancer (2004) 1.20
Angio-tumoral complex in human malignant melanoma characterised by free laminin: ultrastructural and immunohistochemical observations. J Submicrosc Cytol Pathol (1997) 1.19
Persistence of a Salmonella enterica serovar typhimurium DT12 clone in a piggery and in agricultural soil amended with Salmonella-contaminated slurry. Appl Environ Microbiol (2001) 1.18
Hybridization of peptide nucleic acid. Biochemistry (1998) 1.16
High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer (2000) 1.16
Gene targeting approaches using positive-negative selection and large flanking regions. Plant Mol Biol (1997) 1.14
Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann Oncol (2010) 1.13
Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer (2000) 1.12
Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer (2005) 1.12
Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex. J Biol Chem (1995) 1.09
Angio-tumoral laminin in murine tumors derived from human melanoma cell lines. Immunohistochemical and ultrastructural observations. J Submicrosc Cytol Pathol (1998) 1.08
Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer (1998) 1.07
Myofibrosarcoma of subcutaneous soft tissue of the cheek. J Submicrosc Cytol Pathol (1992) 1.06
Myofibrosarcoma of the breast: review of the literature on myofibroblastic tumors and criteria for defining myofibroblastic differentiation. Am J Surg Pathol (1997) 1.05
High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer (1996) 1.04
Contralateral cancerous breast lesions in women with clinical invasive breast carcinoma. Cancer (1986) 1.04
ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol (2008) 1.04
Elevated expression and altered processing of fibulin-1 protein in human breast cancer. Br J Cancer (2003) 1.04
Short-term reproducibility of computed tomography-based lung density measurements in alpha-1 antitrypsin deficiency and smokers with emphysema. Acta Radiol (2004) 1.04
Cystosarcoma phyllodes. A review of 19 cases with emphasis on the occurrence of associated breast carcinoma. Acta Pathol Microbiol Immunol Scand A (1986) 1.01
Metabolism of oral trefoil factor 2 (TFF2) and the effect of oral and parenteral TFF2 on gastric and duodenal ulcer healing in the rat. Gut (1999) 1.00
Studies on oestrogen receptor-alpha and -beta mRNA in breast cancer. Eur J Cancer (2001) 0.99
Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Lett (1994) 0.99
Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet (1994) 0.98
Plasminogen activator and cancer. Eur J Cancer Clin Oncol (1984) 0.98
Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer (1992) 0.97
Pathogenesis of primary shallow chamber angle closure glaucoma. Arch Ophthalmol (1966) 0.97
Stimulation of adenylate cyclase activity in different areas of human brain by substance P. Neuropharmacology (1975) 0.96
ADAM-17: a novel therapeutic target for triple negative breast cancer. Ann Oncol (2012) 0.95
Histologic changes and silicone concentrations in human breast tissue surrounding silicone breast prostheses. Plast Reconstr Surg (1990) 0.95
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol (2011) 0.94
Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem (2001) 0.94
Ets2 transcription factor in normal and neoplastic human breast tissue. Eur J Cancer (2005) 0.93
Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression. Eur J Cancer (2004) 0.93
Subcellular distribution of substance P in bovine hypothalamus and substantia nigra. J Neurochem (1975) 0.93
Peroxidase activity as a possible marker for a functional oestradiol receptor in human breast tumours [proceedings]. Biochem Soc Trans (1977) 0.92
mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors. Breast (2011) 0.91
Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin Cancer Res (1997) 0.91
Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer (1997) 0.90
Multiple forms of plasminogen activator in human breast tumors. Cancer Res (1985) 0.90
Serum sialic acid and CEA concentrations in human breast cancer. Br J Cancer (1980) 0.90
Postoperative shallowing of the anterior chamber. Am J Ophthalmol (1967) 0.90
Urokinase plasminogen activator and prognosis in breast cancer. Lancet (1990) 0.89
Information transfer from DNA to peptide nucleic acids by template-directed syntheses. Nucleic Acids Res (1997) 0.89
Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma. Cancer (1998) 0.89
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol Rep (2005) 0.88
Very low density lipoprotein receptor from mammary gland and mammary epithelial cell lines binds and mediates endocytosis of M(r) 40,000 receptor associated protein. FEBS Lett (1994) 0.88
Rapid automated synthesis via diisopropyl phosphoramidite in situ activation. Chemical synthesis and cloning of a calmodulin gene. Biochem Cell Biol (1986) 0.87
Estradiol receptors in human liver. J Steroid Biochem (1978) 0.87
The half-lap incision and closure in cataract surgery. Am J Ophthalmol (1966) 0.87
Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA. Br J Cancer (2008) 0.87
Ectopic production of intact parathyroid hormone by a squamous cell lung carcinoma in vivo and in vitro. J Clin Endocrinol Metab (1996) 0.87
A tetranectin-related protein is produced and deposited in extracellular matrix by human embryonal fibroblasts. Eur J Biochem (1991) 0.87
Efficacy of a recombinant fowl pox-based Newcastle disease virus vaccine candidate against velogenic and respiratory challenge. Avian Dis (1996) 0.86
Further studies on multiple forms of peptidases in mammalian tissues including intestinal mucosa from children with treated and untreated coeliac disease. Clin Chim Acta (1971) 0.86
Isolated capitate fracture diagnosed by computed tomography. Case report. Handchir Mikrochir Plast Chir (1999) 0.86
Prostate-specific antigen. Superior serum marker for prostatic carcinoma. Ir J Med Sci (1987) 0.86
Ultrastructural and immunohistochemical studies of the periendothelial matrix in human melanoma: evidence for an amorphous matrix containing laminin. J Cutan Pathol (1999) 0.86
High levels of cathepsin B predict poor outcome in patients with breast cancer. Int J Biol Markers (1999) 0.85
Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trial. Ann Rheum Dis (1997) 0.85
Evaluation of some N-acyl analogues of 3,5-bis(arylidene)-4-piperidones for cytotoxic activity. Drug Des Discov (1992) 0.85
Five years experience of breast augmentation using silicone gel prostheses with emphasis on capsule shrinkage. Scand J Plast Reconstr Surg (1984) 0.85
Estrogens, estradiol receptors and peroxidase activity in human mammary carcinomas. Eur J Cancer (1981) 0.84
Melanoma and extravascular migratory metastasis. J Cutan Pathol (2000) 0.84
Afternoon plasma cortisol in depressed patients: a measure of diagnosis or severity? Life Sci (1983) 0.84
A common response element mediates differential effects of phorbol esters and forskolin on type-1 plasminogen activator inhibitor gene expression in human breast carcinoma cells. Eur J Biochem (1994) 0.84
Estradiol receptors in human breast carcinomas assayed by use of monoclonal antibodies. Clin Chem (1986) 0.84
Development of a novel scintillation proximity competitive hybridization assay for the determination of phosphorothioate antisense oligonucleotide plasma concentrations in a toxicokinetic study. Anal Biochem (1996) 0.84